USE OF DAPAGLIFLOZIN (FORXIGA) IN THE MANAGEMENT OF OBESITY AND NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES

Authors

  • Fabricio Malnique
  • Thiago de Almeida Garcia
  • Daniel Martins Ferreira
  • Angelo Augusto Barata Barletta
  • Raíro dos Santos Silvino
  • Pedro Henrique Souza e Silva
  • Gustavo Rosilho Pedroso
  • Beatriz Quatrocci Fávero
  • Fernanda Costa Rodrigues
  • Maria Eduarda Aires Souto
  • Letícia Gaspar Tiago
  • David Alberto Cortez Ayala
  • Diegomaier Nunes Neri
  • Gabriel Marques França
  • Itamara Rodrigues de Melo Vieira
  • Josafá Lima Ribeiro Rocha
  • Gusttavo Henrique Andrade
  • Rickson Cardoso de Oliveira
  • Estevão Missão da Silva
  • Otávio de Meireles Delfino
  • Valéria Goulart Viana
  • Ednei Luiz França Cajá
  • Hugo da Silva Bonfietti
  • Catarina Piñeiro Passos
  • Ariane Marcela Oliveira Ramos

Keywords:

Dapagliflozin, Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Obesity, Integrative Review

Abstract

This integrative review aimed to analyze scientific evidence published between 2020 and 2025 regarding the use of dapagliflozin (Forxiga®) in the management of obesity and non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). The search was conducted in PubMed, SciELO, ScienceDirect, and Consensus Academic Database, using controlled descriptors in Portuguese and English, and including clinical, experimental, and systematic review studies. The evidence analyzed indicates that dapagliflozin shows beneficial potential on glycemic and hepatic metabolism, leading to reductions in hepatic enzymes (ALT, AST, and GGT), improved insulin sensitivity, and decreased accumulation of body and liver fat. Complementary experimental studies demonstrated that the drug acts through the modulation of metabolic and inflammatory pathways, such as FXR/SHP and LXRα/SREBP-1c, reducing hepatic lipogenesis and enhancing fatty acid oxidation. Overall, the reviewed studies suggest that dapagliflozin is a safe and promising therapeutic option for the management of NAFLD in patients with T2DM, although long-term clinical trials with larger samples are still needed to validate its therapeutic potential.

DOI: https://doi.org/10.56238/sevened2025.037-025

Downloads

Published

2025-11-18

Issue

Contemporary Dialogues in Health Sciences - 2° Edição

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Malnique, F., Garcia, T. de A., Ferreira, D. M., Barletta, A. A. B., Silvino, R. dos S., Souza e Silva, P. H., Pedroso, G. R., Fávero, B. Q., Rodrigues, F. C., Souto, M. E. A., Tiago, L. G., Ayala, D. A. C., Neri, D. N., França, G. M., Vieira, I. R. de M., Rocha, J. L. R., Andrade, G. H., de Oliveira, R. C., da Silva, E. M., … Ramos, A. M. O. (2025). USE OF DAPAGLIFLOZIN (FORXIGA) IN THE MANAGEMENT OF OBESITY AND NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES. Seven Editora, 368-379. https://sevenpubl.com.br/editora/article/view/8517